Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has a beta value of 1.38 and has seen 4,866,249 shares traded in the last trading session. The company, currently valued at $25.33 Billion, closed the last trade at $115.58 per share which meant it gained $6.86 on the day or 6.31% during that session. The ALXN stock price is -5.12% off its 52-week high price of $121.5 and 37.13% above the 52-week low of $72.67. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.12 Million shares traded. The 3-month trading volume is 1.81 Million shares.

The consensus among analysts is that Alexion Pharmaceuticals, Inc. (ALXN) is an Overweight stock at the moment, with a recommendation rating of 2.2. None of the analysts rate the stock as a Sell, while 3 rate it as Overweight. 9 out of 22 have rated it as a Hold, with 10 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $2.47.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) trade information

Sporting 6.31% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Sep 15 when the ALXN stock price touched $120.81 or saw a rise of 4.33%. Year-to-date, Alexion Pharmaceuticals, Inc. shares have moved 6.87%, while the 5-day performance has seen it change 6.83%. Over the past 30 days, the shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) have changed 12.25%. Short interest in the company has seen 4.84 Million shares shorted with days to cover at 2.67.

Wall Street analysts have a consensus price target for the stock at $143.11, which means that the shares’ value could jump 23.82% from current levels. The projected low price target is $114 while the price target rests at a high of $175. In that case, then, we find that the current price level is +51.41% off the targeted high while a plunge would see the stock lose -1.37% from current levels.

Alexion Pharmaceuticals, Inc. (ALXN) estimates and forecasts

Figures show that Alexion Pharmaceuticals, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +40.34% over the past 6 months. Other than that, the company has, however, lowered its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are -11.5% and -16.6% for the next quarter. Revenue growth from the last financial year stood is estimated to be +14.5%.

18 analysts offering their estimates for the company have set an average revenue estimate of $1.39 Billion for the current quarter. 18 have an estimated revenue figure of $1.41 Billion for the next quarter concluding in December 01, 2020. Year-ago sales stood $1.26 Billion and $1.37 Billion respectively for this quarter and the next, and analysts expect sales will grow by 10% for the current quarter and 2.6% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +26.8% over the past 5 years. Earnings growth for 2020 is a modest +4.5% while over the next 5 years, the company’s earnings are expected to increase by 11.88%.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)’s Major holders

Insiders own 0.3% of the company shares, while shares held by institutions stand at 95.39% with a share float percentage of 95.67%. Investors are also buoyed by the number of investors in a company, with Alexion Pharmaceuticals, Inc. having a total of 1005 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 18.53 Million shares worth more than $2.08 Billion. As of June 29, 2020, Blackrock Inc. held 8.45% of shares outstanding.

The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 17.01 Million shares as of June 29, 2020. The firm’s total holdings are worth over $1.91 Billion and represent 7.76% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. As of June 29, 2020, the former fund manager holds about 2.73% shares in the company for having 5978281 shares of worth $671Million while later fund manager owns 4.58 Million shares of worth $514.28 Million as of June 29, 2020, which makes it owner of about 2.09% of company’s outstanding stock.